

Global ANGPTL3 Monoclonal Antibody Supply, Demand and Key Producers, 2026-2032

<https://marketpublishers.com/r/G06F9CB8C7CEEN.html>

Date: January 2026

Pages: 95

Price: US\$ 4,480.00 (Single User License)

ID: G06F9CB8C7CEEN

Abstracts

The global ANGPTL3 Monoclonal Antibody market size is expected to reach \$ 289 million by 2032, rising at a market growth of 8.7% CAGR during the forecast period (2026-2032).

In 2025, global ANGPTL3 Monoclonal Antibody production reached approximately 19.72 K Boxes, with an average global market price of around 7497 USD per Box.

ANGPTL3 Monoclonal Antibody is a monoclonal antibody designed to bind and inhibit angiopoietin-like protein 3 (ANGPTL3), a circulating liver-derived protein that regulates lipid metabolism by suppressing lipoprotein lipase (and related pathways). By neutralizing ANGPTL3's activity, these antibodies aim to increase triglyceride-rich lipoprotein clearance and reduce atherogenic lipids (such as LDL cholesterol and triglycerides), and are used or developed for treating severe dyslipidemias and reducing cardiovascular risk. Evolocumab is the only marketed ANGPTL3 Monoclonal Antibody globally. It has been approved by the US FDA for the treatment of homozygous familial hypercholesterolemia (HoFH).

Anti-ANGPTL3 antibodies are compelling because they target a well-defined, liver-driven control point in lipid metabolism that can address a persistent industry pain point: a subset of patients remain at high cardiovascular risk despite today's standard lipid-lowering options, either because of severe inherited dyslipidemias, mixed lipid abnormalities, intolerance, or residual risk that is not fully captured by LDL-centric approaches. By neutralizing ANGPTL3, these antibodies can reduce atherogenic lipoprotein burden through mechanisms that are complementary to statins and PCSK9 inhibitors, offering clinicians a differentiated tool when conventional pathways plateau and enabling a precision-medicine narrative for complex lipid phenotypes where

triglycerides, remnants, and broader dyslipidemia matter. The category is being propelled by structural drivers that have reshaped cardiometabolic drug development: rising global prevalence of obesity and diabetes, stronger emphasis on preventing costly downstream events, increasing sophistication in genetic and biomarker-enabled patient identification, and growing confidence among payers and health systems in high-value biologics that demonstrate meaningful risk reduction in well-defined populations. Anti-ANGPTL3 antibodies have credible market runway as evidence and clinical experience mature, positioning expands from rare and refractory patients toward broader high-risk segments where unmet need remains, and combination strategies with established lipid therapies become more clearly standardized, making the class an attractive long-term opportunity within the evolving cardiometabolic landscape without relying on exaggerated claims.

The upstream raw materials for ANGPTL3 Monoclonal Antibody mainly include ANGPTL3 recombinant protein, CHO cells, etc. Typical raw material suppliers include Thermo Fisher, Merck, Pall, etc. The downstream application is mainly for people with high blood lipids.

The production capacity of ANGPTL3 Monoclonal Antibody production lines varies greatly depending on the type of drug molecule, process complexity, equipment scale, and production mode. The industry gross profit margin is usually in the range of 60%-80%.

This report studies the global ANGPTL3 Monoclonal Antibody production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for ANGPTL3 Monoclonal Antibody and provides market size (US\$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of ANGPTL3 Monoclonal Antibody that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global ANGPTL3 Monoclonal Antibody total production and demand, 2021-2032, (K Boxes)

Global ANGPTL3 Monoclonal Antibody total production value, 2021-2032, (USD Million)

Global ANGPTL3 Monoclonal Antibody production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Boxes), (based on production site)

Global ANGPTL3 Monoclonal Antibody consumption by region & country, CAGR, 2021-2032 & (K Boxes)

U.S. VS China: ANGPTL3 Monoclonal Antibody domestic production, consumption, key domestic manufacturers and share

Global ANGPTL3 Monoclonal Antibody production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Boxes)

Global ANGPTL3 Monoclonal Antibody production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Boxes)

Global ANGPTL3 Monoclonal Antibody production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Boxes)

This report profiles key players in the global ANGPTL3 Monoclonal Antibody market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Regeneron, Eli Lilly, Jiangsu Hengrui Medicine, Cspc Holdings, Suzhou Ribo Life Science, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World ANGPTL3 Monoclonal Antibody market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), volume (production, consumption) & (K Boxes) and average price (USD/Box) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global ANGPTL3 Monoclonal Antibody Market, By Region:

Global ANGPTL3 Monoclonal Antibody Supply, Demand and Key Producers, 2026-2032

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global ANGPTL3 Monoclonal Antibody Market, Segmentation by Type:

Monospecific Antibodies

Bispecific Antibodies

Others

Global ANGPTL3 Monoclonal Antibody Market, Segmentation by Action Mechanism:

Direct Neutralization

Indirect Inhibition

Others

Global ANGPTL3 Monoclonal Antibody Market, Segmentation by Administration Route:

Intravenous Injection

Subcutaneous Injection

Global ANGPTL3 Monoclonal Antibody Market, Segmentation by Application:

Homozygous Familial Hypercholesterolaemia (HoFH)

Others

Companies Profiled:

Regeneron

Eli Lilly

Jiangsu Hengrui Medicine

Cspc Holdings

Suzhou Ribo Life Science

Key Questions Answered:

1. How big is the global ANGPTL3 Monoclonal Antibody market?
2. What is the demand of the global ANGPTL3 Monoclonal Antibody market?
3. What is the year over year growth of the global ANGPTL3 Monoclonal Antibody market?
4. What is the production and production value of the global ANGPTL3 Monoclonal Antibody market?
5. Who are the key producers in the global ANGPTL3 Monoclonal Antibody market?
6. What are the growth factors driving the market demand?

I would like to order

Product name: Global ANGPTL3 Monoclonal Antibody Supply, Demand and Key Producers, 2026-2032

Product link: <https://marketpublishers.com/r/G06F9CB8C7CEEN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G06F9CB8C7CEEN.html>